metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-113 EVALUATION OF THE MELNA AGIB SCALE TO PREDICT MORTALITY IN PATIENTS WITH C...
Journal Information
Vol. 29. Issue S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(December 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(December 2024)
Full text access
P-113 EVALUATION OF THE MELNA AGIB SCALE TO PREDICT MORTALITY IN PATIENTS WITH CIRRHOSIS AND VARICEAL HEMORRHAGE
Visits
10
Miguel Yael Carmona Castillo1, Claudia Leticia Dorantes Nava1, María De Fatima Higuera De La Tijera1, Jose Luis Pérez Hernández1
1 HOSPITAL GENERAL DE MÉXICO, CIUDAD DE MÉXICO, México
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (2)
Special issue
This article is part of special issue:
Vol. 29. Issue S3

Abstracts of the 2023 Annual Meeting of the ALEH

More info
Conflict of interest

No

Introduction and Objectives

Patients with decompensated cirrhosis are at risk of variceal hemorrhage, which increases the risk of mortality. Validated scales exist to assess this risk, but there is currently no scale that evaluates the risk of variceal hemorrhage and death simultaneously. The MELDNa AGIB (acute gastrointestinal bleeding) scale incorporates sodium (Na) levels, albumin levels, the corrected QT interval (QTc), and a history of hemorrhage to calculate mortality at 6 weeks. While it has been evaluated in other centers, further studies are needed to validate its utility. To evaluate the MELDNa-AGIB scale for predicting the risk of mortality in decompensated cirrhotic patients.

Patients / Materials and Methods

This was a retrospective, analytical, observational study conducted on a cohort of patients with decompensated cirrhosis and variceal hemorrhage. The MELDNAAGIB scale was calculated for each patient and compared with other scoring systems, including MELD, MELD NA, MELD LACTATE, and MELD 3.0, to assess its effectiveness. Statistical analysis involved the construction of ROC curves to determine the prognostic value of each scoring system in predicting mortality among patients with variceal bleeding. A significance level of p<0.05 was considered, and sensitivity and specificity were determined based on the cutoff points obtained from the significant ROC curves.

Results and Discussion

A total of 32 patients were included in the study, of whom 56.2% were male, with an average age of 57±11. The etiologies of cirrhosis included alcohol-related, metabolic-associated fatty liver disease (MAFLD), dual injury, hepatitis C virus (HCV), autoimmune hepatitis (AIH), and unidentified causes (34.37%, 31.25%, 21.87%, 6.25%, 3.12%, 3.12%, respectively). Fifty percent of the patients had a prolonged QTc interval (>456ms) as calculated using the Fridericia formula, and 67.2% had a history of previous variceal hemorrhage. The MELDNa-AGIB scale demonstrated an area under the receiver operating characteristic (AUROC) curve of 0.849 (95% confidence interval: 0.681-0.950, p=0.004), with a sensitivity of 87.5% and specificity of 83% when a cutoff point of 17 was applied for MELDNa-AGIB. The AUROC for predicting mortality was significantly lower for MELD/Lactate.

Conclusions

Although the study group was small, the MELDNaAGIB scale showed significant performance in predicting 6-week mortality in patients who developed variceal hemorrhage.

Full Text

Figure 1. Comparative analysis among different scales in patients with variceal hemorrhage and hepatic cirrhosis.

Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos